GlassScriptPhysician profile
Nancy A Mesiha
NPI 1952320293
$9,279.50
in general payments reported to CMS, 2019-2025
41 companies · $1,257 in 2025
The $1,257 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $803 · 2021: $799 · 2022: $1,825 · 2023: $2,243 · 2024: $1,705 · 2025: $1,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,818 · Travel and Lodging: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,818.38 |
| Travel and Lodging | $387.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,525.69 | 2019-2025 | |
| Abbott Laboratories | $763.81 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Pfizer INC. | $686.98 | 2021-2025 | |
| Amgen INC. | $642.52 | 2020-2025 | Repatha, Repatha |
| Abiomed | $629.27 | 2023-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $564.74 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Janssen Pharmaceuticals, INC | $512.86 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $479.10 | 2022-2025 | Emblem Mri S-Icd, Watchman Flx, Cds - Mct/Cem Monitoring |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $408.73 | 2020-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $328.23 | 2021-2024 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $308.42 | 2019-2022 | |
| Heartflow, INC. | $269.36 | 2023-2025 | Ffrct |
| Kestra Medical Technology Services, INC. | $202.26 | 2022-2025 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $192.18 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $186.41 | 2020-2025 | Camzyos, Eliquis |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Mesiha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.